Swayampakula Ramakanth

Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025

Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity

For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity

For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Exclusive: RedHill BioPharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts

BioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst

Exclusive: RedHill BioPharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts

BioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst

HC Wainwright Bullish On Proteon Therapeutics, Sees 105% Potential Upside

H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics

Swayampakula Ramakanth Recent News

Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'

Why This Codexis Analyst Is Confident Stock Is Worth $6

H.C. Wainwright: Time To Buy Novogen

RedHill Bio Price Target Boosted To $32, Buy Reiterated

UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change

UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris